


PLATELETS STRUCTURE AND FUNCTIONS COAGULATION MECHANISMS

DR SYED SHAHID HABIB
MBBS DSDM PGDCR FCPS
Professor
Dept. of Physiology
College of Medicine & KKHU



Vessel injury


Antithrombogenic
(Favors fluid blood)

Thrombogenic
(Favors clotting)

OBJECTIVES

❖ **At the end of the lecture you should be able to describe.....**

- 1. Describe formation and development of platelet**
- 2. Recognize different stages of haemostasis**
- 3. Explain the role of platelets in haemostasis.**
- 4. Recognize different clotting factors & cascade of clotting.**
- 5. Describe the intrinsic, extrinsic and common pathway.**
- 7. Recognize the role of thrombin in coagulation**
- 8. Explain process of fibrinolysis and function of plasmin**



HEMOSTASIS

The spontaneous arrest of bleeding from ruptured blood vessels

STEPS OF HEMOSTASIS

- 1. Vascular Spasm**
- 2. Formation of platelet plug**
- 3. Blood Coagulation & Clot Retraction**
- 4. Fibrinolysis**

1-VASCULAR SPASM (Vascular Constriction)

Immediately After injury there is localized Vasoconstriction.

❖ Causative Factors are three (3)

1. Nervous reflexes
2. Local myogenic spasm
3. Local humoral factors

❖ For smaller vessels


❖ Platelets → Thromboxane A_2 (Vasoconstrictor)

❖ Importance

❖ Crushing injuries → Intense spasm → No lethal loss of blood


TXA₂ is inhibited by aspirin

A. VASOCONSTRICTION





2-FORMATION OF PLATELET PLUG

❖ Importance of platelet plug → small vascular damage




Intact endothelium
secrete prostacyclin





B. PRIMARY HEMOSTASIS

ADP causes stickiness




Serotonin & thromboxane A2 are vasoconstrictors

3-BLOOD COAGULATION


Formation of Clot

- ❖ Blood clotting is the transformation of blood from a liquid into a solid gel form
- ❖ Pathways
 - ❖ Intrinsic
 - ❖ Extrinsic
- ❖ Initiated by: Activator substances from traumatized vascular wall, platelets & blood proteins
- ❖ Begins to develop in
 - ❖ 15-20 sec → Minor trauma
 - ❖ 1-2 min. → Severe trauma

C. SECONDARY HEMOSTASIS




D. THROMBUS AND ANTITHROMBOTIC EVENTS




PLATELETS

Formed by fragmentation from megakaryocytes



SITE OF FORMATION

Bone-marrow



PLATELETS (Characteristics)

SHAPE: MINUTE ROUND OR OVAL DISCS

SIZE: 1-4 μm IN DIAMETER

HALF LIFE: 7-10 DAYS



COUNT: 150,000 – 300,000/ microlitres

LOCATION: 80% in blood & 20% in spleen

- ❖ **Contractile, adhesive, cell fragments.**
- ❖ **Store coagulation factors & enzymes**
- ❖ **Surface Binding sites for fibrinogen**
- ❖ **Surface Glycoprotein Antigens-HPA1.**

FUNCTIONAL CHARACTERISTICS

- Actin and Myosin Molecules
- Endoplasmic Reticulum and Golgi Apparatus
- Mitochondria
- Enzyme Systems For Synthesis Of Prostaglandins
- Fibrin Stabilizing Factor
- Growth Factor



Platelet Ultrastructure

Mitochondria

Microtubules


Alpha Granules
von Willebrand
Factor
Fibrinogen
Chemokines
(PF4, etc.)
Thrombospondin
P-selectin

OCS


Open canalicular
system

Dense Granules
ADP/ATP
Calcium
Serotonin

DB




Platelet Receptors



Platelet functions


Resting platelet




GP IIb/IIIa
receptors

Agonist
→

activated platelet




Fibrinogen




Aggregating
platelets


Platelet function




Adhesion



Activation



Aggregation



Secretion

Activated Platelets

Secrete:

1. 5HT → vasoconstriction
2. Platelet phospholipid (PF3) → clot formation
3. Thromboxane A2 (TXA2) is a prostaglandin formed from arachidonic acid

Function:


- ❖ vasoconstriction
 - ❖ Platelet aggregation
(TXA2 inhibited by aspirin)
4. ADP causes stickiness and enhances aggregation

MECHANISM OF CLOTTING

1. Formation of Prothrombin activator complex (by Extrinsic and Intrinsic Pathways)

2. Conversion of prothrombin into thrombin by PA Complex

3. Conversion of fibrinogen into fibrin



2-CONVERSION OF PROTHROMBIN TO THROMBIN

By Prothrombin Activator Complex

❖ Prothrombin

- ❖ Plasma protein (Alpha₂ globulin)
- ❖ Mol. Wt. - 68,700
- ❖ Plasma conc. - 15 mg/dl
- ❖ Unstable protein
- ❖ Synthesized by liver
- ❖ Vitamin-K is required for synthesis


3-CONVERSION OF FIBRINOGEN TO FIBRIN

Formation Of Clot

❖ Fibrinogen

- ❖ Mol. Wt. – 340,000
- ❖ Plasma conc. – 100 – 700 mg/dl
- ❖ Synthesized in liver

ACTION OF THROMBIN ON FIBRINOGEN TO FORM FIBRIN



BLOOD CLOT

- ❖ A meshwork of fibrin fibres running in all directions entrapping blood cells, platelets and plasma





TABLE 31-5 System for naming blood-clotting factors.

| Factor ^a | Names |
|---------------------|---|
| I | Fibrinogen |
| II | Prothrombin |
| III | Thromboplastin |
| IV | Calcium |
| V | Proaccelerin, labile factor, accelerator globulin |
| VII | Proconvertin, SPCA, stable factor |
| VIII | Antihemophilic factor (AHF), antihemophilic factor A, antihemophilic globulin (AHG) |
| IX | Plasma thromboplastic component (PTC), Christmas factor, antihemophilic factor B |
| X | Stuart–Prower factor |
| XI | Plasma thromboplastin antecedent (PTA), antihemophilic factor C |
| XII | Hageman factor, glass factor |
| XIII | Fibrin-stabilizing factor, Laki–Lorand factor |
| HMW-K | High-molecular-weight kininogen, Fitzgerald factor |
| Pre-Ka | Prekallikrein, Fletcher factor |
| Ka | Kallikrein |
| PL | Platelet phospholipid |

^aFactor VI is not a separate entity and has been dropped.


EXTRINSIC MECHANISM FOR INITIATING CLOTTING


TF or tissue thromboplastin; includes phospholipids from the membranes of the tissue plus a lipoprotein complex that functions mainly as a proteolytic enzyme.




INTRINSIC MECHANISM FOR INITIATING CLOTTING

Trauma to the blood itself or exposure of the blood to collagen (from a traumatized blood vessel wall), foreign surface/glass





ROLES OF THROMBIN IN HEMOSTASIS



CLOT RETRACTION

- ❖ When clot contracts, it expresses most of the fluid from the clot within 20-60 min called → Serum
- ❖ Serum cannot clot
- ❖ Role of platelets in clot formation & retraction
- ❖ Vicious circle of clot formation

ROLE OF CALCIUM IONS IN CLOTTING

❖ **No Ca^{++} → No Clotting**

Blood samples are prevented from clotting by:

❖ **Citrate ions** → Deionization of Ca^{++}

❖ **Oxalate ions** → Precipitate the Ca^{++}

❖ **Heparin** → combines with antithrombin effectiveness increases by 100-1000 fold, Also remove Factors XII, XI, X, and IX

❖ **Warfarin**: ↓ production of Factors VII, IX and X by liver.

❖ **EDTA** → "sequester" metal ions such as Ca^{2+}

LYSIS OF BLOOD CLOTS BY PLASMIN

Formed blood clot can either become fibrous or dissolve.

• **Fibrinolysis (dissolving) = Break down of fibrin by naturally occurring enzyme plasmin therefore prevent intravascular blocking.**

Plasminogen (Profibrinolysin)

**PAI-1
Antiplasmin**


↓ **Antiplasmin from the liver**

- **T-PA (Tissue Plasminogen Activator)**
- **Urokinase-type (uPA)**

Plasmin (Fibrinolysin)

Lysis of clot

Tissue Plasminogen Activator (TPA) used to activate plasminogen to dissolve coronary and cerebral clots.



NATURAL INTRAVASCULAR ANTICOAGULANTS

1. Endothelial Surface Factors

- ❖ Smoothness of Endothelium
- ❖ Glycocalyx Layers
- ❖ Thrombomodulin Protein binds to thrombin → Activates Protein C (with ProtS) → inactivates factors V & VIII and inactivates an inhibitor of tPA → increasing the formation of plasmin.

2. Antithrombin III

- ❖ 85-90 % Thrombin binds with Fibrin
- ❖ 10-15 % Thrombin binds with Antithrombin III

3. Protein C (inhibits Va & VIIIa) & Protein S (Cofactor)

Antithrombin III is a circulating protease blocking clot factors

NATURAL INTRAVASCULAR ANTICOAGULANTS


3. Heparin

- ❖ - ively charged conjugated polysaccharide
- ❖ Increase the effectiveness of Antithrombin III (100-1000 fold)
- ❖ Produced by
 - ❖ Mast cells
 - ❖ Basophil cells
- ❖ Most widely used anticoagulant clinically e.g. in stroke

4. Alpha₂ – Macrogobulin

- ❖ Acts as a binding agent for several coagulation factors

Inactivation of coagulation by antithrombin III




/// Synthesis:
hepatocytes &
endothelial cells.

/// Action:
ATIII + thrombin
→ thrombin-ATIII
complex.

/// Heparin
dramatically
enhances this action

.

PT of Patient/PT of Normal




Protein C:

- Vitamin K-dependent.
- Synthesized by the hepatocytes


Protein C
(inhibits Va & VIIIa)
& **Protein S** (Cofactor)


Activated protein C resistance (APC-R):

is mainly due to a genetic abnormality of clotting factor V called (factor V Leiden mutation).




point mutation in the factor V gene, G1691A in exon 10, leading to Arg506Gln.






Blood
clot
travels
from leg
to lung




MI

DVT & PE


**Placental
infraction**



Stroke



Hemostatic Balance



Laboratory tests of hypercoagulability

Natural anticoagulants

ATIII

Protein C

Protein S

Fibrinolysis

PAI-1

FDPs (D-Dimer)

Laboratory tests of hypercoagulability *cont.*
Coagulation activation markers

Thrombin-Antithrombin complexes (TAT)

Prothrombin fraction 1+2

D-Dimer

Activated protein C Resistance (APCR)

Functional Assay

Genetic assay (Factor V Leiden)

Genotyping:

Factor V Leiden

Prothrombin G20210A

Hyperhomocysteinaemia (MTHFR)

BLEEDING & CLOTTING DISORDERS

- A. Liver diseases & Vitamin-K
deficiency**
- B. Hemophilia**
- C. Thrombocytopenia**

BLEEDING DISORDERS

A. Liver diseases & Vitamin-K deficiency

- ❖ e.g. Hepatitis, Cirrhosis
 - ❖ Decreased formation of clotting factors
 - ❖ Increased clotting time
- ❖ Vitamin K dependent factors
 - ❖ Prothrombin, Factor VII, IX, X

BLEEDING DISORDERS

A. Vitamin-K

- ❖ **Fat soluble vitamin**
- ❖ **Required by liver for formation 4 clotting factors**
- ❖ **Sources**
 - ❖ **Diet**
 - ❖ **Synthesized in the intestinal tract by bacteria**
- ❖ **Deficiency**
 - ❖ **Malabsorption syndromes**
 - ❖ **Biliary obstruction**
 - ❖ **Broad spectrum antibiotics**
 - ❖ **Dietary def (in Neonates)**
 - ❖ **Rx.: Treat the underlying cause Vit K injections**

THROMBOCYTOPENIA

- ❖ Platelet count upto 50,000 ul
- ❖ Less than 10,000 ----- Fatal
- ❖ ETIOLOGY
- ❖ **Decreased production**
 - ❖ Aplastic anemia
 - ❖ Leukemia
 - ❖ Drugs
 - ❖ Infections (HIV, Measles)

THROMBOCYTOPENIA (cont.)

❖ Increased destruction

- ❖ ITP**

- ❖ Drugs**

- ❖ Infections**

❖ Clinical Features

- ❖ Easy bruisability**

- ❖ Epistaxis**

- ❖ Gum bleeding**

- ❖ Hemorrhage after minor trauma**

- ❖ Petechiae/Ecchymosis**

THROMBOCYTOPENIA (cont.)

❖ Diagnosis

- ❖ PLT decreased**
- ❖ B.T increased**

❖ Rx

- ❖ Rx of the underlying cause**
- ❖ PLT concentrates**
- ❖ Fresh whole blood transfusion**
- ❖ Splenectomy**



INHERITED COAGULATION DISORDERS

HEMOPHILIA

❖ HEMOPHILIA A

❖ Classic Hemophilia

❖ 85 % cases

❖ Def. Of factor VIII

❖ HEMOPHILIA B

❖ 15 % cases

❖ Def. Of factor IX

- Transmitted by female X chromosome as recessive trait
- Occurs in males & Females are carriers

Laboratory diagnosis :

The following tests are abnormal:

PTT

Factor VIII or IX or both.

BT & PT are normal.

HEMOPHILIA

❖ Clinical Features

❖ Easy bruising, massive bleeding after trauma or operation, hemorrhages in joints

❖ Factor VIII

❖ Small Comp. → Hemophilia A

❖ Large Comp. → Von-Willebrand's disease

❖ Rx

❖ Injection of factor VIII (Hemophilia A)

❖ Injection of factor IX (Hemophilia B)

ACQUIRED COAGULATION DISORDERS

Disseminated Intravascular Coagulation

- ❖ Wide spread activation of coagulation with formation of microthrombi in small blood vessels.
- ❖ Bleeding diathesis or tendency secondary to depletion of coagulation factors & platelets.

Laboratory diagnosis of DIC:

Low platelet count

Prolonged PT & PTT.

Low fibrinogen or falling fibrinogen on repeated testing.

Fragmented RBCs in blood smear.

Increased FDPs & D-dimer.

VITAMIN K DEFICIENCY

- ❖ Vit. k is required for gamma carboxylation of glutamic acid residues (that is important for calcium binding) of factors II, VII, IX, X, protein C & protein S.
- ❖ In absence of vit k. , gamma carboxylation fail to occur & non functional forms of vit k. dependant factors circulate in the blood.

Laboratory diagnosis:

Both PT&PTT are prolonged.

Platelet count & fibrinogen are normal with absent FDPs.


CHRONIC LIVER DISEASE

- ❖ Decreased clearance of activated clotting factors & increased level of fibrinogen /fibrin degradation products.
- ❖ Liver disease with portal hypertension & splenomegaly --- thrombocytopenia.
- ❖ Hepatoma & cirrhosis--- dysfibrinogenemia which is better to be diagnosed by thrombin time & functional fibrinogen assay.

LIVER DISEASE

- ❖ **The Liver is the major site of clotting factor synthesis**
- ❖ **Hemorrhagic diathesis occur in acute hepatitis or cirrhosis.**
- ❖ **In these conditions, vitamin K- dependant factors II, VII, IX, X, protien C & S are reduced.**
- ❖ **Factors V, VIII are not synthesized by hepatic parenchymal cells but they are increased as acute phase reactants.**
- ❖ **vWF synthesized by endothelial cells is increased as an acute phase reactant.**

Summary of reactions involved in hemostasis.



FACTORS AFFECTING BLOOD PLATELET COUNT

- ❖ **AGE** : ↓ in newborn
- ❖ **Menstrual cycle**:
 - ❖ ↓ prior to menstruation
 - ❖ ↑ After menstruation
- ❖ **Pregnancy**: ↓
- ❖ **Injury**: ↑
- ❖ **Adrenaline**: ↑
- ❖ **Hypoxia**: ↑
- ❖ **Smoking**: ↓
- ❖ **Nutritional deficiencies**: ↓ eg; vitamin b12, folic acid and iron

The fibrinolytic system and its regulation by Protein C





Fig 9-3 Coagulation and its regulation



“ ” activate; “--->” inactivate; -> “ ” source / [transforming](#)


Coagulation Tests

The process of hemostasis occurs in three phases :

1. The vascular **platelet phase**, which assures primary hemostasis ;
2. Activation of the **coagulation cascade**, which assures formation of the clot ;
3. And activation of a series of **control mechanisms, which stop propagation of the clot** and limit activation of the coagulation cascade to the region of endothelial rupture.

Coagulation Tests


1. **Tests of the Vascular Platelet Phase of Hemostasis:**
 - Bleeding Time (BT)
2. **Tests of the Coagulation Cascade:**
 - Clotting Time (CT) or Coagulation time
 - Activated Partial Thromboplastin Time (APTT).
 - Prothrombin Time (PT).
3. **Tests of Fibrinolysis and the Mechanisms That Control Hemostasis:**
 - Fibrin Degradation Products (FDP)



Hypercoagulability:

- ❖ Is a laboratory phenotype whereby activation of the of clotting, fibrinolysis, endothelial cells and platelets are identified.

Thrombus formation: Virchow's triad



Hypercoagulability/Prothrombotic States

Hereditary Hemostatic disorders:

Factor V Leidin

Prothrombin G20210A

Hyperhomocysteinaemia

Deficiencies of AT III, Proteins C & S

Increased FVIII

Acquired Hemostatic disorders:

Raised Levels of fibrinogen & FVII

Antiphospholipid Antibodies (LA & ACAs)

Oestrogen therapy

Pregnancy and its complications

Surgery and prolonged immobility

Major Trauma

Malignancy

Nephrotic Syndrome

Hypercoagulability/Prothrombotic States *cont.*

Acquired Hemostatic disorders : *cont.*

**Dehydration, Hyperviscosity, Polycycaemia,
Thrombocytosis**

Sepsis

Smoking

Obesity


Age

Varicose veins


THANKS




The "Classic" Coagulation System




The Effect of Antithrombin III



The Effect of Protein C



The Effect of TFPI



THE "CLASSIC" COAGULATION SYSTEM

